Palvella Therapeutics, Inc. (PVLA) EBIT Margin (2016 - 2022)
Palvella Therapeutics (PVLA) has disclosed EBIT Margin for 11 consecutive years, with 10770.21% as the latest value for Q3 2024.
- On a quarterly basis, EBIT Margin rose 1106905.0% to 10770.21% in Q3 2024 year-over-year; TTM through Dec 2024 was 186816.67%, a 18692110.0% decrease, with the full-year FY2024 number at 3277.91%, up 356747.0% from a year prior.
- EBIT Margin was 10770.21% for Q3 2024 at Palvella Therapeutics, up from 48466.67% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 10770.21% in Q3 2024 to a low of 48466.67% in Q2 2024.
- A 5-year average of 2357.11% and a median of 187.54% in 2022 define the central range for EBIT Margin.
- Biggest YoY gain for EBIT Margin was 1106905bps in 2024; the steepest drop was -4847690bps in 2024.
- Palvella Therapeutics' EBIT Margin stood at 817.59% in 2020, then surged by 88bps to 99.3% in 2021, then plummeted by -89bps to 187.54% in 2022, then surged by 81bps to 35.78% in 2023, then soared by 30201bps to 10770.21% in 2024.
- Per Business Quant, the three most recent readings for PVLA's EBIT Margin are 10770.21% (Q3 2024), 48466.67% (Q2 2024), and 3742.55% (Q1 2024).